Nanotechnology Perceptions
ISSN 1660-6795
www.nano-ntp.com

Trends and Innovations in Peptide Drug Discovery: A Century of Progress and Future Directions

Siddharth Dhaka[1], Mukund Lata Bharti[2*], Harsh Rastogi[3], Ankur Gupta[4]

[1]Assistant Professor, Department of Pharmaceutics, K.N Modi Institute of Pharmaceutical Education and Research Modinagar, India
[2]Associate Professor, Parmarth College of Pharmacy Hapur By Pass, Achheja, NH24, (Delhi NCR) India
[3]Assistant Professor, Department of Pharmaceutics, Dr. K.N. Modi Institute of Pharmaceutical Education and Research, Modinagar, India
[4]Assistant Professor, School of Pharmacy, Suresh Gyan Vihar University, Jaipur, Rajasthan, India
Email: Pharmofficial2023@gmail.com

Peptide drug discovery has revolutionized modern therapeutics, offering novel treatment avenues for various diseases, including cancer, metabolic disorders, and infectious diseases. Over the past century, advancements in synthesis techniques, such as solid-phase peptide synthesis and recombinant technology, have significantly enhanced the development and scalability of peptide-based drugs. Emerging innovations, including machine learning-driven screening, phage display, and combinatorial chemistry, have accelerated the identification of bioactive peptides with high specificity and efficacy. Additionally, chemical modifications such as PEGylation, cyclization, and unnatural amino acid incorporation have improved the stability, bioavailability, and half-life of peptide drugs. The integration of nanotechnology and venomics has further expanded the potential of peptide therapeutics by enabling targeted drug delivery and enhancing pharmacokinetic properties. Despite these advancements, challenges such as enzymatic degradation and poor oral bioavailability remain key obstacles. However, ongoing research in novel drug delivery systems, including lipidation, nanocarriers, and AI-driven peptide design, is addressing these limitations. With the global peptide therapeutics market experiencing substantial growth, driven by increasing prevalence of chronic diseases and aging populations, peptides are emerging as a dominant class of pharmaceuticals. This review highlights the recent trends, technological breakthroughs, and future prospects in peptide drug discovery, underscoring its transformative impact on modern medicine.

Keywords: Peptide, machine learning, chemical modifications, PEGylation, nanotechnology.

1. Introduction

Peptide drug discovery has a rich history spanning over a century, marked by significant milestones that have transformed therapeutic approaches. The journey began in 1922 with the

introduction of insulin, the first peptide drug derived from bovine and porcine pancreas, revolutionizing diabetes treatment. This groundbreaking development initiated the exploration of peptides in medical applications. A pivotal moment occurred in 1954 when chemist Vincent

du Vigneaud completed the total synthesis of oxytocin and vasopressin, earning him the Nobel Prize in Chemistry in 1955 (Luther et al., 2018). Several technological advancements have significantly propelled peptide drug discovery. In 1963, the invention of solid-phase peptide synthesis (SPPS) automated peptide synthesis, greatly facilitating drug development. The emergence of recombinant technology in the 1980s allowed for large-scale production of peptide drugs, further enhancing their availability and application. The global peptide therapeutics market has shown remarkable growth, valued at $33.3 billion in 2021 and projected to reach $64.3 billion by 2031, with a compound annual growth rate (CAGR) of 6.8%. Some analyses predict even more aggressive growth, estimating market values could reach up to $117.4 billion by 2034 at a CAGR of 10.8% (Brown & Wright, 2016). Currently, over 80 peptide drugs are available globally, addressing critical therapeutic areas such as diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection, and chronic pain. The metabolic segment particularly dominates the market due to the high prevalence of metabolic disorders and an increasing geriatric population (Nestor, 2009). Peptide-based therapeutics offer numerous advantages that enhance their appeal in pharmaceutical research. They exhibit higher clinical trial success rates compared to small molecules and possess the unique ability to target previously "undruggable" protein interactions. Additionally, they typically incur lower production costs than biologics while maintaining high potency and low toxicity. Approximately 140 peptide therapeutics are currently undergoing clinical trials, underscoring the field's dynamic potential (Gentilucci et al., 2010). The growth of the peptide therapeutics market is driven by interconnected factors including an increasing global elderly population demanding advanced therapeutic solutions for age-related chronic conditions (Jost et al., 1987) and a rising prevalence of chronic diseases such as cancer and diabetes. Technological advancements play a crucial role in this dynamic landscape; innovations in peptide stabilization, drug delivery systems, and personalized medicine are enhancing treatment efficacy. Recent developments have improved peptides' ability to overcome traditional limitations like enzymatic degradation and metabolic instability (Zaoral et al., 1967). North America currently leads the peptide therapeutics market due to major drug manufacturers like Novo Nordisk, Eli Lilly, and AstraZeneca investing heavily in research and development. However, the Asia-Pacific region is emerging as a significant growth market, particularly in countries like China and India. This region's market potential is bolstered by an aging population, increased healthcare investments, rising chronic disease prevalence, and growing government support for biomedical research. For instance, China is projected to achieve a CAGR of 8.7% in peptide therapeutics from 2024 to 2034 due to robust pharmaceutical manufacturing capabilities and heightened public awareness of advanced healthcare solutions. Figure 1 shows the peptide drug design cycle, integrating key factors such as in vitro activity, plasma stability, physical stability, and chemical stability. It highlights the role of SAR analysis, structural biology, and in silico modeling in optimizing peptide properties. Additionally, formulation requirements, including pH, dose, and excipients, are considered for enhanced drug stability and efficacy.



Fig. 1: Peptides optimization in drug delivery system.

2. Technological Advancements in Peptide Drug Discovery

1. Screening Techniques

Technological advancements in screening techniques have significantly accelerated peptide drug discovery. Modern approaches utilize automated systems and computational tools to identify potential therapeutic peptides with high specificity and efficacy (Melin et al., 1986). Techniques such as affinity-based screening and functional assays allow researchers to rapidly assess interactions between peptides and target molecules. These advancements have improved the accuracy and efficiency of drug discovery, reducing time and costs associated with traditional screening methods (Du Vigneaud et al., 1960).

Phage Display and Combinatorial Chemistry

Phage display and combinatorial chemistry have revolutionized peptide identification by enabling the discovery of novel peptides with high affinity for specific targets. Phage display technology involves the presentation of peptide libraries on the surface of bacteriophages, allowing for the selection of peptides that bind tightly to a given target (Hope et al., 1962). Meanwhile, combinatorial chemistry generates diverse peptide libraries through systematic variations in molecular structures, enhancing the ability to identify potent drug candidates. Together, these methods have transformed the way researchers develop peptide-based therapeutics (Manning et al., 1973).

Table 1: Screening Techniques in Peptide Drug Discovery

Screening Technique	Description	Advantages	Examples
Phage Display	Uses bacteriophages to present peptides for selection against a target	Rapid identification of high-affinity peptides	Development of peptide-based therapeutics like Tezepelumab

Combinatorial Chemistry	Generates large libraries of peptides with diverse sequences	Increases the chances of finding bioactive peptides	Discovery of antimicrobial and anticancer peptides
High-Throughput Screening (HTS)	Rapidly screens vast peptide libraries for biological activity	Accelerates drug discovery process	Screening for enzyme inhibitors and receptor ligands
Machine Learning-Based Screening	Uses AI algorithms to predict peptide interactions with targets	Reduces experimental cost and time	AI-driven peptide drug discovery for cancer treatment

High-Throughput Screening

High-throughput screening (HTS) plays a crucial role in modern peptide drug discovery by enabling the rapid exploration of vast peptide libraries (Kyncl & Rudinger, 1970). Automated robotic systems and advanced analytical techniques allow researchers to test thousands to millions of peptide candidates in a short period. This approach significantly increases the likelihood of identifying promising drug candidates with desirable properties. HTS has also facilitated the optimization of peptide structures, improving their stability, bioavailability, and therapeutic potential (Kruszynski et al., 1980).

2. Chemical Modifications

Chemical modifications are essential for improving the therapeutic potential of peptides by enhancing their stability, bioavailability, and resistance to enzymatic degradation. Since natural peptides often suffer from poor metabolic stability and rapid clearance from the body, various chemical strategies have been developed to optimize their properties (Meraldi et al., 1977). These modifications help to extend the half-life of peptides, increase their binding affinity, and improve their ability to cross biological barriers, making them more effective as drugs (Walter & Du Vigneaud, 1966).

Cyclization

Cyclization is a widely used strategy to enhance peptide stability by introducing a covalent bond between different parts of the peptide chain. This modification reduces the peptide's flexibility, making it less susceptible to enzymatic degradation while maintaining its biological activity (Walter & Du Vigneaud, 1965). Cyclized peptides often exhibit improved receptor binding and increased resistance to proteolysis, which contributes to their enhanced therapeutic efficacy. This technique has been successfully applied in the development of peptide drugs with prolonged activity in the body (Yamanaka et al., 1970). Figure 2 compares peptides with small molecules and biologics, highlighting their advantages and drawbacks. Peptides offer high specificity, good efficacy, and low immunogenicity but suffer from low stability and short half-life. Their advantages over biologics include better membrane permeability and lower cost, making them promising therapeutic candidates.



Fig. 2: Comparison of Peptides, Small Molecules, and Biologics: Advantages and Drawbacks

D-Amino Acid Substitutions

Substituting naturally occurring L-amino acids with their D-amino acid counterparts is an effective method for improving peptide stability. D-amino acids are not easily recognized by proteolytic enzymes, making the peptide more resistant to degradation (Sweeney et al., 1990). This modification also enhances the structural rigidity of peptides, potentially increasing their affinity for target receptors. By incorporating D-amino acid substitutions, researchers can develop peptide drugs with longer half-lives and improved pharmacokinetic profiles (Manning et al., 2012).

Incorporation of Unnatural Amino Acids

The incorporation of unnatural amino acids is another advanced technique used to optimize peptide therapeutics. These synthetic amino acids can introduce unique chemical properties that enhance stability, receptor selectivity, and bioavailability (Manning et al., 2008). They also enable the development of peptides with novel mechanisms of action, reducing the risk of immune system recognition and degradation. This approach has led to the creation of innovative peptide-based drugs with superior therapeutic potential (Ling et al., 1973).

3. Conjugation and Fusion Strategies

Conjugation and fusion strategies are widely used in peptide drug discovery to enhance stability, prolong half-life, and improve pharmacokinetic properties. These strategies involve the attachment of molecules such as polyethylene glycol (PEG) or lipids to peptides, which help in reducing enzymatic degradation and renal clearance. Such modifications significantly enhance the therapeutic potential of peptides by improving their circulation time in the body and reducing immunogenicity (Theodoropoulou & Stalla, 2013).

PEGylation and Lipidation to Extend Peptide Half-Life

PEGylation, the attachment of polyethylene glycol (PEG) chains to peptides, is a well-established technique to increase the half-life of peptide drugs. Studies have shown that PEGylation can extend the plasma half-life of peptides from minutes to several hours or even days. For example, PEGylation of the peptide drug liraglutide (a GLP-1 receptor agonist) increased its half-life to 13 hours, compared to 2 hours for its non-PEGylated counterpart. Similarly, pegvisomant, a PEGylated growth hormone receptor antagonist, has a half-life of about 6 days, significantly improving its therapeutic efficacy (Biron et al., 2008). Lipidation, the process of attaching fatty acid chains to peptides, is another approach that enhances peptide stability by increasing its binding to albumin, thereby slowing down renal clearance. Semaglutide, a lipidated GLP-1 agonist, demonstrates a 7-day half-life, allowing for once-weekly dosing compared to daily administration required for non-lipidated GLP-1 analogs. These modifications contribute to sustained drug action and better patient compliance (Janecka et al., 2001).

Improved Pharmacokinetic Properties

By enhancing peptide stability and reducing degradation, PEGylation and lipidation significantly improve pharmacokinetics. PEGylated peptides show increased solubility, reduced immunogenicity, and prolonged circulation time in the bloodstream. Lipidation enhances peptide transport across membranes, improving absorption and bioavailability. Studies indicate that lipidation can increase bioavailability by up to 50%, depending on the peptide structure and formulation (Vale et al., 1979).

Reduced Dosing Frequency

One of the key advantages of conjugation strategies is the reduced dosing frequency, leading to better patient adherence. For example, the lipidated peptide semaglutide allows for once-weekly administration, whereas its predecessor, liraglutide, requires daily dosing. Similarly, PEGylated interferon-alpha (Pegasys) enables once-weekly dosing, compared to the thrice-weekly regimen of standard interferon-alpha. These advancements make peptide drugs more convenient for patients while maintaining their therapeutic effectiveness (Susini & Buscail, 2006).

3. Market and Research Trends

Market Growth

The peptide drug discovery market has been experiencing significant growth due to advancements in screening technologies, chemical modifications, and formulation strategies. In 2020, the global peptide drug discovery market was valued at approximately $560 million, driven by increasing demand for peptide-based therapeutics in oncology, metabolic disorders, and infectious diseases. The market is projected to grow at a compound annual growth rate (CAGR) of 10.5%, reaching over $1.2 billion by 2030. The rise in chronic diseases, coupled with advancements in peptide synthesis and drug delivery, is fueling this expansion (De Jong et al., 2009).

Peptide Drug Pipeline and Clinical Development

Peptide-based drugs continue to dominate the pharmaceutical pipeline, with over 40 peptide drugs currently in Phase 3 clinical development. These candidates span therapeutic areas such as oncology, endocrinology, cardiovascular diseases, and infectious diseases. For instance, tirzepatide, a dual GIP/GLP-1 receptor agonist for type 2 diabetes, has demonstrated promising results in late-stage trials, showing superior glucose control and weight reduction. Additionally, peptide vaccines for cancer immunotherapy and infectious diseases (COVID-19 and influenza) are being actively developed, further expanding the market potential (Kwekkeboom et al., 2001). With growing investments from biotech and pharmaceutical companies, as well as increased regulatory approvals, peptide-based therapeutics are expected to play a crucial role in the future of drug discovery. The market's robust growth and expanding research pipeline indicate a promising outlook for peptide drugs as a key segment in the global pharmaceutical industry (Adessi & Soto, 2002).

4. Emerging Technologies and Future Directions

Advanced Screening Methods

The rapid evolution of technology has introduced advanced screening methods that significantly enhance peptide drug discovery. Traditional experimental screening methods are now being complemented by computational approaches, allowing for faster and more precise identification of promising peptide candidates. High-throughput sequencing, microfluidic screening, and artificial intelligence-driven modeling are transforming the efficiency of peptide discovery and optimization (Gentilucci et al., 2010).

Machine Learning Algorithms for Predicting Peptide-Protein Interactions

Machine learning (ML) algorithms have become an essential tool in peptide drug discovery by enabling accurate prediction of peptide-protein interactions. These AI-driven models analyze vast biological datasets to identify binding affinities, optimize peptide sequences, and predict their stability and bioactivity. Recent studies have demonstrated that ML-based approaches can reduce peptide screening time by up to 70% compared to traditional experimental methods. Additionally, deep learning models are improving the identification of therapeutic peptides for cancer, metabolic disorders, and neurodegenerative diseases with greater precision (Jost et al., 1987).

Nanotechnology Integration for Improved Drug Delivery

Nanotechnology is playing a crucial role in enhancing the stability, bioavailability, and targeted delivery of peptide-based therapeutics. Nanocarriers such as lipid nanoparticles, polymeric nanoparticles, and dendrimers help protect peptides from enzymatic degradation while enabling controlled and sustained drug release (Zaoral et al., 1967). For example, peptide-loaded nanoparticles have been shown to increase drug half-life by up to 5 times, allowing for more efficient delivery to specific tissues and reducing the required dosage. This technology is particularly promising for peptide-based cancer therapies, where targeted delivery can minimize off-target effects (Dimson, 1977).

Integrated Venomics Approaches

Venomics the study of animal venoms has emerged as a powerful approach for discovering novel bioactive peptides. Many venom-derived peptides exhibit high specificity and potency, making them excellent candidates for drug development (Melin et al., 1986). Integrated venomics approaches combine genomics, transcriptomics, and proteomics to systematically explore venom compositions and identify peptides with therapeutic potential. Notable examples include exenatide (derived from Gila monster venom) for diabetes treatment and captopril (derived from Brazilian viper venom) for hypertension. Future research in venomics is expected to unlock new classes of peptide drugs for pain management, cardiovascular diseases, and autoimmune disorders (Du Vigneaud et al., 1960). As these emerging technologies continue to evolve, they will drive the next generation of peptide-based therapeutics, offering higher efficacy, better patient outcomes, and novel treatment options across various disease areas (Hope et al., 1962).

5. Challenges and Opportunities

Despite significant advancements, peptide drug discovery still faces several challenges that hinder widespread clinical adoption. One of the major limitations of peptide-based drugs is their susceptibility to enzymatic degradation. Since peptides are naturally occurring biomolecules, they are rapidly broken down by proteolytic enzymes in the gastrointestinal tract and bloodstream, leading to short half-lives. This necessitates frequent dosing or chemical modifications such as PEGylation, cyclization, or the incorporation of non-natural amino acids to enhance stability (Manning et al., 1973). Peptide drugs often suffer from poor bioavailability, especially when administered orally. Many peptides have high molecular weights and hydrophilic properties, which prevent efficient absorption through the intestinal membrane. As a result, most peptide therapeutics require injection-based delivery, limiting patient compliance. Research into novel drug delivery systems, such as nanocarriers and oral peptide formulations, is ongoing to address this challenge (Kyncl & Rudinger, 1970; Kruszynski et al., 1980).

6. Conclusion:

Peptide drug discovery is rapidly evolving, driven by technological advancements, innovative screening methods, and novel drug delivery strategies. The integration of machine learning, nanotechnology, and venomics is revolutionizing the way peptides are identified, optimized, and delivered, overcoming traditional challenges such as enzymatic degradation and poor bioavailability. With a projected market growth of 10.5% CAGR and over 40 peptide-based drugs in Phase 3 clinical trials, peptides are emerging as a crucial class of therapeutics for oncology, metabolic disorders, infectious diseases, and neurological conditions. Research is also expanding into previously untreatable diseases, offering new hope for patients with rare and chronic conditions. By addressing current limitations and leveraging cutting-edge innovations, peptide-based therapies are set to redefine modern medicine, providing highly specific, safer, and more effective treatment options. As new discoveries continue to unfold, peptide drugs have the potential to significantly enhance patient outcomes and global

healthcare solutions in the coming years.

References

[1] A. Alinaghi, M. R. Rouini, F. J. Daha, and H. R. Moghimi, "Hydrogel-embeded vesicles, as a novel approach for prolonged release and delivery of liposome, in vitro and in vivo," J. Liposome Res., vol. 23, pp. 235–243, 2013, doi: 10.3109/08982104.2013.799179.

[2] D. Alizadeh, M. Trad, N. T. Hanke, et al., "Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T cell transfer in breast cancer," Cancer Res., vol. 74, pp. 104–118, 2014, doi: 10.1158/0008-5472.CAN-13-1545.

[3] I. M. Basurto, J. A. Passipieri, G. M. Gardner, et al., "Photoreactive hydrogel stiffness influences volumetric muscle loss repair," Tissue Eng. Part A, vol. 28, pp. 312–329, 2022, doi: 10.1089/ten.TEA.2021.0137.

[4] M. D. Baumann, C. E. Kang, C. H. Tator, and M. S. Shoichet, "Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury," Biomaterials, vol. 31, pp. 7631–7639, 2010, doi: 10.1016/j.biomaterials.2010.07.004.

[5] C. Blanpain, "Stem cells: skin regeneration and repair," Nature, vol. 464, pp. 686–687, 2010, doi: 10.1038/464686a.

[6] F. Manea, F. B. Houillon, L. Pasquato, and P. Scrimin, "Nanozymes: Gold-nanoparticle-based transphosphorylation catalysts," Angew. Chem. Int. Ed., vol. 43, no. 45, pp. 6165–6169, 2004, doi: 10.1002/anie.20046064978.

[7] L. Gao, J. Zhuang, L. Nie, et al., "Intrinsic peroxidase-like activity of ferromagnetic nanoparticles," Nat. Nanotechnol., vol. 2, no. 9, pp. 577–583, 2007, doi: 10.1038/nnano.2007.26058.

[8] X. Wang, X. J. Gao, L. Qin, et al., "Eg occupancy as an effective descriptor for the catalytic activity of perovskite oxide-based peroxidase mimics," Nat. Commun., vol. 10, no. 1, p. 704, 2019, doi: 10.1038/s41467-019-08657-58.

[9] H. Dong, W. Du, J. Dong, et al., "Depletable peroxidase-like activity of Fe_3O_4 nanozymes accompanied with separate migration of electrons and iron ions," Nat. Commun., vol. 13, no. 1, p. 5365, 2022, doi: 10.1038/s41467-022-33098-y8.

[10] C. Gu, L. Zhang, T. Hou, et al., "Unveiling the glucose oxidase-like and catalase-like activities of highly conjugated 3,4,9,10-perylenetetracarboxylic dianhydride for boosting biofuel cells," Adv. Funct. Mater., vol. 34, p. 2400617, 2024, doi: 10.1002/adfm.2024006178.

[11] H. R. R., D. Dhamecha, S. Jagwani, et al., "Local drug delivery systems in the management of periodontitis: a scientific review," J. Controlled Release, vol. 307, pp. 393–409, 2019, doi: 10.1016/j.jconrel.2019.06.038.

[12] N. Harbeck and M. Gnant, "Breast cancer," Lancet, vol. 389, pp. 1134–1150, 2017, doi: 10.1016/S0140-6736(16)31891-8.

[13] H. He, Z. Fei, T. Guo, et al., "Bioadhesive injectable hydrogel with phenolic carbon quantum dot supported Pd single atom nanozymes as a localized immunomodulation niche for cancer catalytic immunotherapy," Biomaterials, vol. 280, p. 121272, 2022, doi: 10.1016/j.biomaterials.2021.121272.

[14] J. He, W. Zhang, Y. Cui, et al., "Multifunctional Cu_2Se/F127 hydrogel with SOD-like enzyme activity for efficient wound healing," Adv. Healthcare Mater., vol. 13, p. e2303599, 2024, doi: 10.1002/adhm.202303599.

[15] X. Y. Feng, H. Fu, Z. Y. Bai, P. Li, X. L. Song, and X. P. Hu, "Colorimetric detection of glucose by a hybrid nanomaterial based on amplified peroxidase-like activity of ferrosoferric oxide modified with gold-platinum heterodimer," New J. Chem., vol. 46, pp. 239–249, 2021.

[16] L. Zhao, X. Ren, J. Zhang, et al., "Dendritic silica with carbon dots and gold nanoclusters for dual nanozymes," New J. Chem., vol. 44, pp. 1988–1992, 2020.

[17] B. W. Liu and J. W. Liu, "Surface modification of nanozymes," Nano Res., vol. 10, pp. 1125–1148, 2017.

[18] A. H. Y. Lee, W. S. Kang, and J. S. Choi, "Highly enhanced enzymatic activity of Mn-induced carbon dots and their application as colorimetric sensor probes," Nanomaterials, vol. 11, p. 3046, 2021.

[19] S. X. Sun, Z. J. Zhang, Y. Xiang, M. W. Cao, and D. Y. Yu, "Amino acid-mediated synthesis of the ZIF-8 nanozyme that reproduces both the zinc-coordinated active center and hydrophobic pocket of natural carbonic anhydrase," Langmuir, vol. 38, pp. 1621–1630, 2022.

[20] V. Jain, S. Bhagat, M. Singh, V. Bansal, and S. Singh, "Unveiling the effect of 11-MUA coating on biocompatibility and catalytic activity of a gold-core cerium oxide-shell-based nanozyme," RSC Adv., vol. 9, pp. 33195–33206, 2019.

[21] A. S. Hoffman, "Hydrogels for biomedical applications," Adv. Drug Deliv. Rev., vol. 64, pp. 18–23, 2012, doi: 10.1016/j.addr.2012.09.010.

[22] E. M. Ahmed, "Hydrogel: Preparation, characterization, and applications: A review," J. Adv. Res., vol. 6, no. 2, pp. 105–121, 2015, doi: 10.1016/j.jare.2013.07.006.

[23] H. Hosseini, H. Tenhu, and S. Hietala, "Rheological properties of thermoresponsive nanocomposite hydrogels," J. Appl. Polym. Sci., vol. 133, no. 11, 2016, doi: 10.1002/app.43123.

[24] C. Chang and L. Zhang, "Cellulose-based hydrogels: present status and application prospects," Carbohydr. Polym., vol. 84, no. 1, pp. 40–53, 2011, doi: 10.1016/j.carbpol.2010.12.023.

[25] K. Nielsen, H. Vorum, N. Ehlers, N. Aagaard, J. Hjortdal, and B. Honoré, "Tear film proteins deposited on high water content contact lenses identified with two-dimensional gel electrophoresis and mass spectrometry," Acta Ophthalmol., vol. 93, no. 7, pp. 658–662, 2015, doi: 10.1111/aos.12800.

[26] Y. Li, R. Fu, Z. Duan, et al., "Adaptive hydrogels based on nanozyme with dual-enhanced triple enzyme–like activities for wound disinfection and mimicking antioxidant defense system," Adv. Healthcare Mater., vol. 11, p. 2101849, 2022, doi: 10.1002/adhm.202101849.

[27] Y. Li, R. Fu, Z. Duan, et al., "Construction of multifunctional hydrogel based on the tannic acid-metal coating decorated MoS_2 dual nanozyme for bacteria-infected wound healing," Bioact. Mater., vol. 9, pp. 461–474, 2022, doi: 10.1016/j.bioactmat.2021.07.023.

[28] Y. Li, R. Fu, Z. Duan, et al., "Injectable hydrogel based on defect-rich multi-nanozymes for diabetic wound healing via an oxygen self-supplying cascade reaction," Small, vol. 18, p. e2200165, 2022, doi: 10.1002/smll.202200165.

[29] L. Long, R. Cai, J. Liu, et al., "A novel nanoprobe based on core-shell Au@Pt@mesoporous SiO_2 nanozyme with enhanced activity and stability for mumps virus diagnosis," Front. Chem., vol. 8, pp. 463–465, 2020, doi: 10.3389/fchem.2020.00463.

[30] W. Luo, C. Zhu, S. Su, et al., "Self-catalyzed, self-limiting growth of glucose oxidase-mimicking gold nanoparticles," ACS Nano, vol. 4, pp. 7451–7458, 2020, doi: 10.1021/nn102592h.

[31] Z. Luo, Y. Chen, S. Chen, et al., "Comparison of inhibitors of superoxide generation in vascular smooth muscle cells," Br. J. Pharmacol., vol. 157, pp. 935–943, 2009, doi: 10.1111/j.1476-5381.2009.00259.x.

[32] H. Aygun and A. Bilginoglu, "Effect of tadalafil and nitric oxide agonist sodium nitroprusside on penicillin-induced epileptiform activity," Neurol. Res., vol. 42, pp. 39–46, 2020.

[33] T. Feng, J. Wan, P. Li, H. Ran, H. Chen, Z. Wang, and L. Zhang, "A novel NIR-controlled NO release of sodium nitroprusside-doped Prussian blue nanoparticle for synergistic tumor treatment," Biomaterials, vol. 214, p. 119213, 2019.

[34] W. Wang, D. Ding, K. Zhou, M. Zhang, W. Zhang, F. Yan, and N. Cheng, "Prussian blue and collagen loaded chitosan nanofibers with NIR-controlled NO release and photothermal activities for wound healing," J. Mater. Sci. Technol., vol. 93, pp. 17–27, 2021.

[35] G. Biscari, M. Malkoch, C. Fiorica, et al., "Gellan gum-dopamine mediated in situ synthesis of silver nanoparticles and development of nano/micro-composite injectable hydrogel with antimicrobial activity," Int. J. Biol. Macromol., vol. 258 Pt 1, p. 128766, 2024.

[36] L. Xu, Y. Y. Wang, J. Huang, C. Y. Chen, Z. X. Wang, and H. Xie, "Silver nanoparticles: Synthesis, medical applications and biosafety," Theranostics, vol. 10, pp. 8996–9031, 2020.

[37] P. Mazur, I. Skiba-Kurek, P. Mrowiec, E. Karczewska, and R. Drożdż, "Synergistic ROS-associated antimicrobial activity of silver nanoparticles and gentamicin against Staphylococcus epidermidis," Int. J. Nanomed., vol. 15, pp. 3551–3562, 2020.

[38] A. Anwar, M. Imran, and H. M. N. Iqbal, "Smart chemistry and applied perceptions of enzyme-coupled nano-engineered assemblies to meet future biocatalytic challenges," Coord. Chem. Rev., vol. 493, p. 215329, 2023, doi: 10.1016/j.ccr.2023.215329.

[39] Y. Guan, F. Xu, L. Sun, et al., "Hydrogen peroxide electrochemical sensor based on Ag/Cu bimetallic nanoparticles modified on polypyrrole," Sensors, vol. 23, no. 20, p. 8536, 2023, doi: 10.3390/s23208536.
[40] X. Hu, G. Wang, K. Fang, R. Li, C. Dong, S. Shi, and H. Li, "The construction of Fe-porphyrin nanozymes with peroxidase-like activity for colorimetric detection of glucose," Anal. Biochem., vol. 675, p. 115224, 2023, doi: 10.1016/j.ab.2023.115224.
[41] X. Gao, H. Pan, Y. Wei, M. Ye, C. Qiao, J. Wang, Q. Liu, and C. Zhou, "A novel bienzymatic bioreactor based on magnetic hierarchical porous MOF for improved catalytic activity and stability: Kinetic analysis, thermodynamics properties and biocatalyst applications," Biochem. Eng. J., vol. 197, p. 108995, 2023, doi: 10.1016/j.bej.2023.108995.
[42] S. Sahar, S. Sun, A. Zeb, L. Jin, Y. Gao, L. Tian, W. Wang, A.-W. Xu, and Z. Mao, "Multi-enzyme mimics – cracking the code of subcellular cascade reactions and their potential biological applications," Mater. Chem. Front., vol. 7, no. 15, pp. 3037–3072, 2023, doi: 10.1039/D2QM01373H.
[43] X. Li, Y. Pan, J. Zhou, G. Yi, C. He, Z. Zhao, and Y. Zhang, "Hyaluronic acid-modified manganese dioxide-enveloped hollow copper sulfide nanoparticles as a multifunctional system for the co-delivery of chemotherapeutic drugs and photosensitizers for efficient synergistic antitumor treatments," J. Colloid Interface Sci., vol. 605, pp. 296–310, 2022.
[44] H. Gong, Y. Hua, Y. Wang, X. Zhang, H. Wang, Z. Zhao, and Y. Zhang, "Fabrication of a novel macrophage-targeted biomimetic delivery composite hydrogel with multiple-sensitive properties for tri-modal combination therapy of rheumatoid arthritis," Int. J. Pharm., vol. 665, p. 124708, 2024.
[45] S. Lin, H. Chen, R. Wang, T. Jiang, R. Wang, and F. Yu, "Hollow silver-gold alloy nanoparticles for enhanced photothermal/photodynamic synergetic therapy against bacterial infection and acceleration of wound healing," Biomater. Sci., vol. 11, pp. 4874–4889, 2023.
[46] C. Qi, Y. Zhang, and J. Tu, "Facile synthesis of ε-poly-L-lysine-conjugated ZnO@PDA as photothermal antibacterial agents for synergistic bacteria killing and biofilm eradication," Biochem. Eng. J., vol. 186, p. 108569, 2022.
[47] N. Chakraborty, D. Jha, H. K. Gautam, and I. Roy, "Peroxidase-like behavior and photothermal effect of chitosan-coated Prussian-blue nanoparticles: Dual-modality antibacterial action with enhanced bioaffinity," Mater. Adv., vol. 1, pp. 774–782, 2020.
[48] Wolf, "PDMS with designer functionalities—Properties, modifications strategies, and applications," Prog. Polym. Sci., vol. 83, p. 97, doi: 10.1016/j.progpolymsci.2018.06.001.
[49] Wu, "Stem cell-laden injectable hydrogel microspheres for cancellous bone regeneration," Chem. Eng. J., vol. 393, doi: 10.1016/j.cej.2020.124715.
[50] Xie, "High-efficient engineering of osteo-callus organoids for rapid bone regeneration within one month," Biomaterials, vol. 288, doi: 10.1016/j.biomaterials.2022.121741.
[51] Wang, "Organoid bioinks: construction and application," Biofabrication, vol. 16, doi: 10.1088/1758-5090/ad467c.
[52] Urness, "Liquid deposition photolithography for submicrometer resolution three-dimensional index structuring with large throughput," Light Sci. Appl., vol. 2, p. e56, doi: 10.1038/lsa.2013.12.
[53] Glangchai, "Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles," J. Control. Release, vol. 125, p. 263, doi: 10.1016/j.jconrel.2007.10.021.
[54] Lee, "Glacier moraine formation-mimicking colloidal particle assembly in microchanneled, bioactive hydrogel for guided vascular network construction," Adv. Healthc. Mater., vol. 4, p. 195, doi: 10.1002/adhm.201400153.
[55] L. Nerurkar, S. Siebert, I. B. McInnes, and J. Cavanagh, "Rheumatoid arthritis and depression: an inflammatory perspective," Lancet Psychiatry, vol. 6, pp. 164–173, 2019.
[56] L. J. O'Neil, et al., "Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis," Sci. Adv., vol. 6, p. eabd2688, 2020.
[57] Q. Zhang, et al., "Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis," Nat. Nanotechnol., vol. 13, pp. 1182–1190, 2018.
[58] G. Nygaard and G. S. Firestein, "Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes," Nat. Rev. Rheumatol., vol. 16, pp. 316–333, 2020.
[59] J. S. Smolen, D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery, "New therapies for treatment of

rheumatoid arthritis," Lancet, vol. 370, pp. 1861–1874, 2007.
[60] J. S. Smolen and G. Steiner, "Therapeutic strategies for rheumatoid arthritis," Nat. Rev. Drug Discov., vol. 2, pp. 473–488, 2003.
[61] Z. Liu, M. Tang, J. Zhao, R. Chai, and J. Kang, "Looking into the future: toward advanced 3D biomaterials for stem-cell-based regenerative medicine," Adv. Mater., vol. 30, p. 1705388, 2018.
[62] L. Tan, et al., "Engineered probiotics biofilm enhances osseointegration via immunoregulation and anti-infection," Sci. Adv., vol. 6, p. eaba5723, 2020.
[63] B. Yuan, et al., "A biomimetically hierarchical polyetherketoneketone scaffold for osteoporotic bone repair," Sci. Adv., vol. 6, p. eabc4704, 2020.
[64] Y. Zhao, et al., "Infliximab-based self-healing hydrogel composite scaffold enhances stem cell survival, engraftment, and function in rheumatoid arthritis treatment," Acta Biomater., vol. 121, pp. 653–664, 2021.
[65] B. P. Purcell, et al., "Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition," Nat. Mater., vol. 13, pp. 653–661, 2014.
[66] D. Wang, et al., "Self-assembled single-atom nanozymes for enhanced photodynamic therapy treatment of tumor," Nat. Commun., vol. 11, p. 357, 2020.
[67] H. Bai, et al., "3D printed porous biomimetic composition sustained release zoledronate to promote osteointegration of osteoporotic defects," Mater. Des., vol. 189, p. 108513, 2020.
[68] X. Zheng, Q. Liu, C. Jing, Y. Li, D. Li, W. Luo, Y. Wen, Y. He, Q. Huang, Y.-T. Long, and C. Fan, "Catalytic gold nanoparticles for nanoplasmonic detection of DNA hybridization," Angew. Chem. Int. Ed., vol. 50, pp. 11994–11998, 2011, doi: 10.1002/anie.201105121.
[69] Y. Hu, H. Cheng, X. Zhao, J. Wu, F. Muhammad, S. Lin, J. He, L. Zhou, C. Zhang, Y. Deng, P. Wang, Z. Zhou, S. Nie, and H. Wei, "Surface-enhanced Raman scattering active gold nanoparticles with enzyme-mimicking activities for measuring glucose and lactate in living tissues," ACS Nano, vol. 11, no. 6, pp. 5558–5566, 2017, doi: 10.1021/acsnano.7b00905.
[70] L. Gao, J. Zhuang, L. Nie, et al., "Intrinsic peroxidase-like activity of ferromagnetic nanoparticles," Nat. Nanotechnol., vol. 2, pp. 577–583, 2007, doi: 10.1038/nnano.2007.260.
[71] S. Dong, Y. Dong, B. Liu, J. Liu, S. Liu, Z. Zhao, W. Li, B. Tian, R. Zhao, F. He, S. Gai, Y. Xie, P. Yang, and Y. Zhao, "Guiding transition metal-doped hollow cerium tandem nanozymes with elaborately regulated multi-enzymatic activities for intensive chemodynamic therapy," Adv. Mater., vol. 34, p. 2107054, 2022, doi: 10.1002/adma.202107054.
[72] M. Vázquez-González, W.-C. Liao, R. Cazelles, S. Wang, X. Yu, V. Gutkin, and I. Willner, "Mimicking horseradish peroxidase functions using Cu^{2+}-modified carbon nitride nanoparticles or Cu^{2+}-modified carbon dots as heterogeneous catalysts," ACS Nano, vol. 11, no. 3, pp. 3247–3253, 2017, doi: 10.1021/acsnano.7b00352.
[73] Y. Ouyang, Y. Biniuri, M. Fadeev, P. Zhang, R. Carmieli, M. Vázquez-González, and I. Willner, "Aptamer-modified Cu^{2+}-functionalized C-dots: Versatile means to improve nanozyme activities—'aptananozymes'," J. Am. Chem. Soc., vol. 143, no. 30, pp. 11510–11519, 2021, doi: 10.1021/jacs.1c03939.